亚太药物研发领袖峰会2017

About APRDL 2017

The Pharma and Biotech sectors are at a pivotal point in their evolution. Pharmaceutical companies are likely to continue to increase the percentage of their R&D work that is outsourced in Asia. This trend will continue to be driven by the pursuit of Open Innovation in University-Industrial Partnership, Improving R&D cost efficiency as well as effectiveness. Beyond generating one-off savings, the emphasis will move to streamlining the outsourcing operating model, risk management, complexity management and lean process improvement. Doing more R&D with less and smartly.

The Asia Pharma R&D Leaders Summit 2017 ( APRDL 2017 ) will bring in fresh perspectives and scientific advancement on popular therapeutic areas in Neurodegenerative Diseases; Cancer, Diabetes and metabolic diseases which big pharma R&D are heavily investing in Asia. The new perspective will be discussed in parallel with pharma partnering models, licensing opportunities, risk management approaches, outsourcing strategies, Precision Medicine, IP management and latest pharma research advancement on sequencing, biomarkers, preclinical imaging, data management to optimize your pharma R&D cost efficiency and gain competitiveness in Asia. Come and join Asia Pharma R&D Leaders 2017 – the most premier pharma R&D event in China with Asia perspectives:

With over 50 speakers and estimation to bring over 250 pharma R&D professionals, the key conference topics will cover:

-- Asian Strategies: How Big Pharma and Biotech companies manage their R&D activities
-- How can companies drive maximum value from M&A and licensing deals
-- Government initiatives in China 13th 5 years’ plan benefit for your research projects in China
-- Explore mass in-licensing opportunities in Asia emerging markets in response to new world R&D order
-- Novel Technologies and Approaches for Drug Discovery
-- Precision Medicine & Personalized Healthcare
-- Research Ethics & Ethical Approval
-- Develop new business models in 2017 and beyond for pharma R&D geared toward cost efficiency and ROI improvement
-- Navigate Asia market trends for heavily invested therapeutics areas: Oncology, Neurodegenerative and Metabolic diseases
-- Lay foundations for effective partnership with top CROs, Biotech and Academia
-- Tapping into Funding & Investment Opportunities in Pharmaceutical R&D in Asia
-- Challenges of Conducting Clinical Trials in APAC, Regulatory Requirements & IRB Approval Process
-- Open Innovation in University-Industrial Partnership for BioMedical Technology Development
-- Personalized anticancer drug discovery & development in Asia

On behalf of the committee, we sincerely hope primary discussions, topics and invitees would come across your scientific and strategic interests And the whole summit will be consisted of keynote speeches, panel/roundtable discussions, open Q&A sessions, booth and poster exhibition and cozy, guided networking sessions for all professionals and management who are working for the pharmaceutical research and development programs in Asia.